title: Use of bevacizumab in the treatment of metastatic colorectal cancer.
abstract: The Cancer Drugs Fund may allow more patients in England access to clinically effective cancer therapies. In this article oncologists already familiar with the clinical evidence, and experienced in treating with bevacizumab, share practical recommendations on optimal first-line use of this treatment for metastatic colorectal cancer.
authors.affiliation: Queens Hospital, Romford, Essex RM7 0AG, UK. Sherif.Raouf@bhrhospitals.nhs.uk
authors.forename: Sherif
authors.initials: S
authors.lastname: Raouf
authors.forename: John
authors.initials: J
authors.lastname: Bridgewater
authors.forename: Richard
authors.initials: R
authors.lastname: Ellis
authors.forename: David
authors.initials: D
authors.lastname: Ferry
authors.forename: Mark
authors.initials: M
authors.lastname: Hill
authors.forename: Harpreet
authors.initials: H
authors.lastname: Wasan
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D018572:Disease-Free Survival; D006801:Humans; D009362:Neoplasm Metastasis; D016032:Randomized Controlled Trials as Topic; D013222:State Medicine; D006113:United Kingdom; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab